Important announcement concerning Temple Health and Keystone First. Our provider agreement with Keystone First, is scheduled to end on July 31st. Learn about your options to continue receiving care at Temple Health.
Breadcrumb
Cell Lines
Technology Transfer Contacts
- Inna Khartchenko, MS, MBA
Director, Technology Transfer
215-214-3989
[email protected] - Natalia Shalginskikh, PhD
Licensing Associate,
Technology Transfer
267-963-7121
[email protected] - Tatiana Venkova, PhD
Licensing Associate,
Technology Transfer
215-983-0257
[email protected]
(technologies available for licensing)
Note: Links to Patents may require a browser newer than Internet Explorer 9, such as Chrome, Safari, Firefox, Edge, or Internet Explorer 11TECH ID | TITLE | LEAD INVENTOR | CONTACT |
---|---|---|---|
01-04 |
FC-muMCL1 murine mantle cell lymphoma model cell line |
Mitchell Smith |
|
01-21 |
N38-2C12/Va14+ T-cell hybridoma |
Kyoko Hayakawa |
|
01-22
|
N38-2C12/ Bv8.2 T-cell hybridoma |
Kyoko Hayakawa |
|
03-21 |
OVCAR-3 ovarian carcinoma cell line from a patient refractory to cisplatin |
Thomas Hamilton |
|
03-22 |
OVCAR-4 ovarian carcinoma cell line from a patient refractory to cisplatin |
Thomas Hamilton |
|
03-23 |
OVCAR-5 ovarian carcinoma cell line from untreated advanced tumor |
Thomas Hamilton |
|
03-26 |
A2780 ovarian cancer cell line (cisplatin sensitive) derived from patient prior to treatment
|
Thomas Hamilton |
|
03-32R |
MOVCAR cell lines |
Denise Connolly |
|
04-30 |
A2780/CP70 and CP30 cisplatin-resistant cell lines |
Thomas Hamilton |
|
05-18 |
Mesothelioma cell lines |
Joseph Testa |
|
07-14 |
PE01 human ovarian cancer cell line
|
Thomas Hamilton |
|
07-28 |
N38-3C3 NK T-cell hybridoma |
Kyoko Hayakawa |
|
95-13 |
HepAD38: tet-inducible HBV expression cell line |
Christoph Seeger |
|
120-RK |
Inducible HeLa TI-C GFP cells |
Richard Katz |
|
133-JR |
bsMCF: triple-negative breast cancer, Boyden chamber-selected tumorigenic cells |
Jose Russo |
|
134-JR |
trMCF: triple-negative breast cancer, estradiol-transformed cells |
Jose Russo |
|
150-WM |
LMH-D2 duck hepatitis B virus-expressing cell line
|
William Mason |
|
156-KH |
N37-1A12 T-cell hybridoma |
Kyoko Hayakawa |
|
191-CS |
Dstet5 cells |
Christoph Seeger |
|
249-JT |
Murine Thymic Lymphoma cells from Lck-Akt2 mice |
Joseph Testa |
|
263-DB |
Liposarcoma cell line LS2
|
Margaret von Mehren |
|
272-JT |
APPL1KO/WT MEF (murine embryonic fibroblasts) |
Joseph Testa |
|
295-CS |
HeLa HCV replicon |
Christoph Seeger |
|
310-MC |
Inflammatory breast cancer cell line FC-IBC02 |
Massimo Cristofanilli |
|
344-JR |
T4 cell line
|
Jose Russo |
|
353-DW |
Scid.adh: a thymic cell line that mimics T-cell development invitro |
David Wiest |
|
379-CS |
NTCP-HepG2 cell line |
Christoph Seeger |
|
382-CS |
NTCP-Cas9-HepG2 cell line
|
Christoph Seeger |
|
384-CS |
Hep AD38-Cas9 cell line
|
Christoph Seeger |
|
451-HB |
HEK293-MRP3 cells
|
Elizabeth Hopper-Borge |
|
452-HB |
HEK293-pcDNA Vector control cell line for MRP cells
|
Elizabeth Hopper-Borge |
|
453-HB |
HEK293-MRP7-C17 cells |
Elizabeth Hopper-Borge |
|
454-HB |
MEF 405 (MRP -/-, Pgp -/-) cells |
Elizabeth Hopper-Borge |
|
455-HB |
MEF 205 (MRP +/+, Pgp -/-) cells |
Elizabeth Hopper-Borge |
|
456-HB |
HEK293-MRP7-C18 cells |
Elizabeth Hopper-Borge |
|
457-HB |
MEF 237 (MRP -/-, Pgp +/+) cells |
Elizabeth Hopper-Borge |
|
535-HB |
Wild type (WT) mouse embryonic fibroblasts (MEFs): control for 454-HB;455-HB and 457-HB |
Elizabeth Hopper-Borge |
|
458-JR |
LmMCF cell line: triple-negative breast cancer cells derived from lung metastasis of bsMCF cells |
Jose Russo |
|
459-JR |
XtMCF cell line: triple-negative breast cancer cells derived from xenograft of bsMCF cells |
Jose Russo |
|
468-SA |
EBV-B cell line from a patient with renal cancer carrying mutation in the intronic region of RRM2B gene |
Sanjeevani Arora |
|
478-LW |
B16BL6-D5-HER2 cell line |
Louis Weiner |
|
503-MC |
EMF-011 cell line from patient with inflammatory breast cancer |
Massimo Cristofanilli |
|
504-AKS |
BEAS-2B-CSC 1196 xenograft-derived human bronchial epithelial cells (non-tumor derived) |
Andres Klein-Szanto |
|
505-AKS |
BEAS-2B-BW 1799 xenograft-derived human bronchial epithelial cells (control) |
Andres Klein-Szanto |
|
506-AKS |
BEAS-2B-CSC 1198 xenograft-derived human bronchial epithelial cells (non-tumor derived) |
Andres Klein-Szanto |
|
507-AKS |
BEAS-2B-CSC 1170-I xenograft-derived human bronchial epithelial cells (tumor derived) |
Andres Klein-Szanto |
|
525-EC |
Immortalized human pancreatic cancer-associated fibroblasts engineered to limit alpha 5 integrin expression |
Edna Cukierman |
|
526-EC |
Immortalized human pancreatic cancer-associated fibroblasts engineered to limit αV integrin expression |
Edna Cukierman |
|
527-EC |
Immortalized human pancreatic cancer-associated fibroblasts engineered to limit β3 integrin expression |
Edna Cukierman |
|
528-EC |
Immortalized human pancreatic cancer-associated fibroblasts engineered to limit β5 integrin expression |
Edna Cukierman |
|
529-EC |
Immortalized human pancreatic cancer-adjacent fibroblastic cells engineered to limit α5 integrin expression |
Edna Cukierman |
|
530-EC |
Immortalized human pancreatic cancer-adjacent fibroblastic cells engineered to limit αV integrin expression |
Edna Cukierman |
|
531-EC |
Immortalized human pancreatic cancer-adjacent fibroblastic cells engineered to limit β3 integrin expression |
Edna Cukierman |
|
532-EC |
Immortalized human pancreatic cancer-adjacent fibroblastic cells engineered to limit β5 integrin expression |
Edna Cukierman |
|
537-DC |
MOVCAR cell lines |
Denise Connolly |
|
540-KC |
SKOV3 cells expressing high levels of SLAMF7 |
Kerry Campbell |
|
556-IA |
KPC3 murine PDAC cell lines |
Igor Astsaturov |
|
557-IA |
KPC4b murine PDAC cell lines |
Igor Astsaturov |
Share
-
Share with Facebook
-
Share with twitter
-
Share with email
-
Print this